Document Detail


Progesterone receptor modulators and progesterone antagonists in women's health.
MedLine Citation:
PMID:  11108892     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Both progesterone receptor modulators (PRMs) as well as pure progesterone antagonists (PAs) have numerous proven and potential therapeutic applications in female health care. Mifepristone, a PRM with only marginal agonistic activity, together with a prostaglandin can terminate pregnancies of less than 9 weeks duration; mifepristone is also used in the preparation of women at later gestational stages whose pregnancies are terminated with prostaglandins or surgery. Mifepristone causes expulsion of the uterine contents following intrauterine fetal death and promotes dilation of the non-pregnant primigravid uterus. It is also effective in the treatment of missed abortion. Together with methotrexate, mifepristone can be used in the medical treatment of ectopic pregnancy. Both PAs and PRMs display antiproliferative effects on the endometrium. Because of this, they have application in the treatment of endometriosis, an estrogen-dependent condition. They may also be utilized to reduce myoma size, acting as both a PA and antiproliferative agent. Unlike GnRH agonists, long-term use in endometriosis and myoma is not associated with loss of bone and hypoestrogenism. PRMs may also be useful in IVF programs to prevent a premature LH surge and to delay the emergence of the implantation window. Some PRMs have potential use as hormone replacement therapy in women during menopause or in those with dysfunctional uterine bleeding.
Authors:
I M Spitz; K Chwalisz
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Steroids     Volume:  65     ISSN:  0039-128X     ISO Abbreviation:  Steroids     Publication Date:    2000 Oct-Nov
Date Detail:
Created Date:  2000-12-18     Completed Date:  2001-03-29     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  0404536     Medline TA:  Steroids     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  807-15     Citation Subset:  IM    
Affiliation:
Institute of Hormone Research, Shaare Zedek Medical Center, 91031, Jerusalem, Israel. spitz@roskefeller.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abortifacient Agents, Nonsteroidal / pharmacology,  therapeutic use
Animals
Female
Genital Diseases, Female / drug therapy
Hormone Antagonists / pharmacology,  therapeutic use*
Humans
Mifepristone / pharmacology,  therapeutic use
Pregnancy
Progesterone / antagonists & inhibitors*
Receptors, Progesterone / agonists,  antagonists & inhibitors
Chemical
Reg. No./Substance:
0/Abortifacient Agents, Nonsteroidal; 0/Hormone Antagonists; 0/Receptors, Progesterone; 57-83-0/Progesterone; 84371-65-3/Mifepristone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pregnancy termination.
Next Document:  The use of progesterone antagonists and progesterone receptor modulators in contraception.